CLDX Stock Catalyst: Celldex Therapeutics Announces Positive Phase 3 Results for Barzolvolimab

Celldex Therapeutics, Inc. announced on 2026-09-22 Celldex announced positive results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab, which met primary and all key secondary endpoints, with results compared to placebo.

1,939 patients. The announcement cited 12 weeks, 24 weeks, 52 weeks, 9.3%, 12.6%, 42.4%, 45.7%, 42.1%, 44.0%, 15.4%, 17.6%, 49.0%, 54.0%, 45.1%, 48.4%, 15.1%, 55.3%, 41.7%, 44.3%, 46.4%, 33.8%, 33.7%, 62.7%, 74.3%, 66.3%, 66.2%, and n=963.

Celldex Therapeutics, Inc. has a free float of 61,336,644 shares and 78,529,532 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.